Welcoming Dr Nicola Heron as our new trustee
We are delighted to welcome Dr Nicola Heron, who is Chief Strategic Impact Officer at Medicines Discovery Catapult (MDC), onto our Board of Trustees. Dr Heron brings over 24 years of experience in life science including holding senior positions in organisations including AstraZeneca and the NHS.
She has experience of pharmaceuticals, medical devices and diagnostics, and gained a PhD in Chemistry in Boston, USA and an MBA from the University of Sheffield. Nicola joined AstraZeneca in 1998 as a medicinal chemist. She moved to Sheffield Teaching Hospital NHS Foundation Trust in 2009, where she was Programme Director of the NIHR Healthcare Technology Cooperative, D4D. She is an accomplished scientist with over 45 publications and board-level experience in multiple life sciences organisations.
As well as being one of our Trustees, she is a non-executive director at Cheshire and Warrington LEP Science and Growth Corridor sub-board and Chair of the Industry Board for the Manchester Clinical Research Facility.
Nicola joined MDC in 2018 as Head of Collaborative R&D, joining the Executive team in January 2021. In her role as Chief Strategic Impact Officer, Nicola builds and maintains MDC’s strategic national relationships.
We are grateful that she is willing to share her knowledge and experience with us, and we look forward to her being a part of our organisation as we move towards exciting projects such as the Tinnitus Biobank.